As a consequence of this discovery, a TYK2 inhibitor is currently being trialled for use in treating patients with CD, systemic lupus erythematosus (SLE) and psoriasis (Ps), with promising initial results [17]. This evidence concerns the gene TYK2 and systemic lupus erythematosus.